Furthermore, immunostaining revealed that most of the patients with invasive breast carcinoma (IBC) strongly expressed Ki-67 (Ki-67+) and BCL-2 (BCL-2+), with proportions of 85.5% (65/76) and 57.9% (44/76) respectively. The gene discussed is BCL2; the disease is invasive breast carcinoma.